Studies on the toxicological detection of the designer drug 4-bromo-2,5-dimethoxy-beta-phenethylamine (2C-B) in rat urine using gas chromatography-mass spectrometry.
Denis S Theobald, Giselher Fritschi, Hans H Maurer
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences February 1, 2007 DOI: 10.1016/j.jchromb.2006.08.049 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Rat urine |
| Intervention | 2C-B |
| Dose | common drug abusers' dose |
| Keywords | Drug detection Drug testing Drug screening Substance detection Illicit drug identification Drug analysis Forensic toxicology Clinical toxicology Drug toxicology Toxicological analysis Biomarker detection Breakdown product identification Drug metabolite analysis Metabolic profiling Analytical chemistry Gc-ms Gas chromatography-mass spectrometry Chemical analysis Analytical methods Designer drugs Novel psychoactive substances Synthetic drugs 2c-b Illicit drugs |
| Citations | 37 |
| Key findings | The GC-MS procedure can detect 2C-B metabolites in rat urine and should be suitable for human urine. |
Abstract
The phenethylamine-derived designer drug 4-bromo-2,5-dimethoxy-beta-phenethylamine (2C-B) is known to be extensively metabolized in various species including humans. In rat urine, 2C-B was found to be excreted mainly via its metabolites. In the current study, the toxicological detection of these metabolites in the authors' systematic toxicological analysis (STA) procedure was examined. The STA procedure using full-scan GC-MS allowed proving an intake of a common drug abusers' dose of 2C-B by detection of the O-demethyl deaminohydroxy and two isomers of the O-demethyl metabolites in rat urine. Assuming similar metabolism, the described STA procedure should be suitable for proof of an intake of 2C-B in human urine.